The COVID-19 pandemic brought messenger RNA (mRNA) vaccines to the forefront of global health care. After their clinical trial stages, the first COVID-19 mRNA vaccine was administered on 8 December ...

Machine learning reveals unique COVID vaccine immune signatures in people living with HIV, with differences in antibodies, cytokines, and T cell responses.

Wyss Institute's DoriVac combined vaccine and adjuvant technology uses nanoscale precision enabled by DNA origami to induce broad immunity against ...

The COVID-19 pandemic brought messenger RNA (mRNA) vaccines to the forefront of global health care. After their clinical trial stages, the first COVID-19 mRNA vaccine was administered on 8 December ...

The study offers one of the most detailed maps yet of how human antibody responses vary from person to person.

ADMA posts 18% Q4 revenue growth as Asceniv drives record 2025 sales, with 2026 revenues seen topping $635M and margins set to expand.

A futuristic “DNA origami” vaccine platform may one day outperform mRNA shots while being easier to produce and distribute. Credit: Shutterstock Scientists have developed a new DNA origami–based ...

Creating a clear and well-defined bioanalytical methodology to quantify humoral and cellular immune responses is critical for ...

FY 2025 Total Revenue of $510 Million, Representing 20% Year-Over-Year GrowthFY 2025 ASCENIV Revenue Grew to $363 Million, Representing 51% ...

Since the program’s authorization in May 2025, between prior repurchases and the ASR, ADMA will have repurchased approximately $160 million of its common stock to date. Management believes these ...